Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Pinealon and Semax — mechanism, dosing, side effects, legal status, and pricing.
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Khavinson bioregulator series, studied for its potential role in regulating pineal gland function and neuroprotective signaling pathways in preclinical models.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-10) with a Pro-Gly-Pro C-terminal extension for metabolic stability. It was developed at the Institute of Molecular Genetics (Russian Academy of Sciences) and registered as a drug in Russia in 1994. It is not FDA-approved.
Pinealon
Semax
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Pinealon
Semax
COA corpus from Disclosed Labs — independently tested batches only.
Pinealon
30
COAs
98.7%
Avg purity
9
Labs
Semax
82
COAs
99.5%
Avg purity
16
Labs
Khavinson et al. (Rejuvenation Research, 2011, PMID 21978084) reported that Pinealon suppressed reactive oxygen species accumulation, reduced cell death, and modulated cell-cycle progression across multiple cell types under oxidative stress, with the authors suggesting direct genome-level interaction. Arutjunyan et al. (International Journal of Clinical and Experimental Medicine, 2012, PMID 22567179) reported that Pinealon administered to pregnant rats on a methionine (hyperhomocysteinemia) diet improved spatial learning and reduced ROS accumulation in cerebellar neurons of offspring. The evidence base is dominated by Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and has not been independently replicated in Western clinical trials. No Phase II or III trials exist; Pinealon is not FDA-approved.
Semax's evidence base is primarily Russian-language clinical literature. Gusev, Skvortsova and colleagues reported improved neurological recovery in acute hemispheric ischemic stroke when Semax was added to conventional therapy (Zh Nevrol Psikhiatr, 1997; PMID 11517472), and subsequent Russian studies extended use to cerebrovascular insufficiency (PMID 15792140). Preclinical work by Dolotov, Myasoedov and colleagues demonstrated that intranasal Semax rapidly elevates BDNF protein and TrkB activation in rat hippocampus and basal forebrain (Brain Res 2006, PMID 16996037; J Neurochem 2006, PMID 16635254). Genome-wide transcriptional analysis by Medvedeva et al. in rat focal ischemia showed Semax modulates a broad panel of immune-response and vascular-system genes (BMC Genomics 2014, PMID 24661604). Western evidence is limited; Semax has not been evaluated by the FDA and has no pivotal trials in the US or EU.
Pinealon and Semax are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs